Histone deacetylase inhibitors:research advances
10.13220/j.cnki.jipr.2017.12.004
- VernacularTitle:组蛋白去乙酰化酶抑制剂的研究进展
- Author:
Zhao-Ji DONG
1
,
2
;
Cheng HAN
;
Jing-Jing LIU
;
Rui-Luan WANG
;
Wei GU
;
Ai-Hua NIE
Author Information
1. 500021南宁,广西医科大学
2. 100850北京,军事科学院军事医学研究院毒物药物研究所
- Keywords:
histone deacetylase inhibitors(HDACi);
structural transformation;
drug combination
- From:
Journal of International Pharmaceutical Research
2017;44(12):1098-1106,1124
- CountryChina
- Language:Chinese
-
Abstract:
Histone deacetylases(HDAC)and its inhibitors have been the hot spots in the field of cancer-treatment.At pres?ent,six HDAC inbibitors(HDACi)have been approved by FDA for the treatment of various hematological neoplasms and solid tu?mors.Besides,a number of new HDACi are undergoing clinical trials in different stages or preclinical experiments,which have shown great inhibitory activities.However,a series of side effects and dose-dependent problems have appeared due to the poor selectivity of inhibitors in HDAC subtypes.So a new HDACi with high-selectity to HDAC subtypes or drug-combination will be of importance to im?prove the therapeutic effect.This review highlights the structure modification in HDACi and multiple drugs combination to summarize the latest evolution of HDACi.
